High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma: A Multicenter, International Data-Sharing American Joint Committee on Cancer Study.
AJCC
Multicenter
Pathology
Retinoblastoma
Staging
Journal
Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
30
01
2022
revised:
20
03
2022
accepted:
08
04
2022
pubmed:
19
4
2022
medline:
27
7
2022
entrez:
18
4
2022
Statut:
ppublish
Résumé
To determine the value of clinical features for advanced intraocular retinoblastoma as defined by the eighth edition of the American Joint Committee on Cancer (AJCC) cT3 category and AJCC Ophthalmic Oncology Task Force (OOTF) Size Groups to predict the high-risk pathologic features. International, multicenter, registry-based retrospective case series. Eighteen ophthalmic oncology centers from 13 countries over 6 continents shared evaluations of 942 eyes enucleated as primary treatment for AJCC cT3 and, for comparison, cT2 retinoblastoma. International, multicenter, registry-based data were pooled from patients enrolled between 2001 and 2013. High-risk pathologic features were defined as AJCC categories pT3 and pT4. In addition, AJCC OOTF Size Groups were defined as follows: (1) less than half, (2) more than half but less than two thirds, (3) more than two thirds of globe volume involved, and (4) diffuse infiltrating retinoblastoma. Statistical risk of high-risk pathologic features corresponding to AJCC cT3 subcategories and AJCC OOTF Size Groups. Of 942 retinoblastoma eyes treated by primary enucleation, 282 (30%) showed high-risk pathologic features. Both cT subcategories and AJCC OOTF Size Groups (P < 0.001 for both) were associated with high-risk pathologic features. On logistic regression analysis, cT3c (iris neovascularization with glaucoma), cT3d (intraocular hemorrhage), and cT3e (aseptic orbital cellulitis) were predictive factors for high-risk pathologic features when compared with cT2a with an odds ratio of 2.3 (P = 0.002), 2.5 (P = 0.002), and 3.3 (P = 0.019), respectively. Size Group 3 (more than two-thirds globe volume) and 4 (diffuse infiltrative retinoblastoma) were the best predictive factors with an odds ratio of 3.3 and 4.1 (P < 0.001 for both), respectively, for high-risk pathologic features when compared with Size Groups 1 (i.e., < 50% of globe volume). The AJCC retinoblastoma staging clinical cT3c-e subcategories (glaucoma, intraocular hemorrhage, and aseptic orbital cellulitis, respectively) as well as the AJCC OOTF Size Groups 3 (tumor more than two thirds of globe volume) and 4 (diffuse infiltrative retinoblastoma) both allowed stratification of clinical risk factors that can be used to predict the presence of high-risk pathologic features and thus facilitate treatment decisions.
Identifiants
pubmed: 35436535
pii: S0161-6420(22)00284-6
doi: 10.1016/j.ophtha.2022.04.006
pmc: PMC9329269
mid: NIHMS1814230
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
923-932Subventions
Organisme : NCI NIH HHS
ID : K08 CA232344
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Références
J Pediatr Hematol Oncol. 2021 Aug 1;43(6):e841-e847
pubmed: 33769386
Int J Ophthalmol. 2017 Jun 18;10(6):961-967
pubmed: 28730089
Br J Ophthalmol. 2015 Oct;99(10):1366-71
pubmed: 25873648
Eur J Ophthalmol. 2019 Mar;29(2):262-268
pubmed: 29890860
Ophthalmology. 2015 Jun;122(6):1165-72
pubmed: 25841975
Ophthalmol Retina. 2020 Jun;4(6):630-639
pubmed: 32387053
Ophthalmology. 2020 Dec;127(12):1719-1732
pubmed: 32512116
JAMA Ophthalmol. 2022 Jan 01;140(1):30-36
pubmed: 34762098
Ophthalmology. 2021 May;128(5):740-753
pubmed: 33007338
Ophthalmology. 2006 Dec;113(12):2276-80
pubmed: 16996605
J Pediatr Hematol Oncol. 2009 May;31(5):325-9
pubmed: 19415010
Pediatr Blood Cancer. 2013 Apr;60(4):688-93
pubmed: 22997170
JAMA Ophthalmol. 2016 May 01;134(5):584-591
pubmed: 26986443
Int Ophthalmol Clin. 2015 Winter;55(1):77-96
pubmed: 25436495
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Surv Ophthalmol. 2002 Jan-Feb;47(1):1-16
pubmed: 11801265
Ophthalmology. 2014 May;121(5):1109-18
pubmed: 24589388
Indian J Ophthalmol. 2018 Dec;66(12):1833-1838
pubmed: 30451190
Pediatr Blood Cancer. 2012 Mar;58(3):356-61
pubmed: 21721113
JAMA Oncol. 2020 May 1;6(5):685-695
pubmed: 32105305
Ophthalmology. 2020 Dec;127(12):1733-1746
pubmed: 32526306
J Clin Oncol. 2019 Nov 1;37(31):2883-2891
pubmed: 31539297
Ophthalmology. 2019 Sep;126(9):1306-1314
pubmed: 30986443
Lancet Glob Health. 2022 Mar;10(3):e307-e308
pubmed: 35093203
Saudi J Ophthalmol. 2013 Jul;27(3):147-50
pubmed: 24227979